<p>China NT Pharma Group Co. Ltd. has announced a strategic shift towards developing new medical and health business models with a focus on light asset operations based on artificial intelligence. The company is implementing a first-phase plan to establish a full-cycle smart health ecosystem platform targeting “testing, treatment, and rehabilitation” in the bone health sector. As part of this initiative, the company is advancing its bone health testing business, including the acquisition of 100% of the issued shares in a related entity through the allotment and issuance of new shares. The Group aims to expedite business integration, improve liquidity, and strengthen its financial position through these measures. Further updates on the Group’s development will be provided in compliance with relevant listing rules. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China NT Pharma Group Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260128-12003907), on January 28, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

512290

China NT Pharma Group Announces Shift to AI-Based Light Asset Operations and Launch of Smart Health Ecosystem Platform Focused on Bone Health